Zero unexpected in-life adverse findings across 162 rats in a repeat 13-week study removes the primary obstacle for NMRA-215, Neumora Therapeutics' (Nasdaq: NMRA) oral NLRP3 inhibitor targeting obesity and cardiometabolic disease. The Watertown, Mass. company disclosed the results in a July 27, 2026 8-K filing, attributed the prior adverse findings to study-conduct discrepancies rather than the compound, and said it plans to submit an investigational new drug application in the fourth quarter of 2026, with a Phase 1 study start targeted before year-end.
The problem the repeat study was designed to fix
The prior 13-week rat study recorded unexpected in-life adverse findings in 5 of 142 animals. That count triggered a for-cause audit. The audit identified various discrepancies and returned a number of critical observations about how that original study was conducted. Based on those findings, Neumora concluded the adverse events were not attributable to NMRA-215. The repeat enrolled 162 animals. None showed the unexpected in-life findings seen before.
What the pre-clinical profile claims
NMRA-215 is designed as a brain-penetrant NLRP3 inhibitor, a mechanism tied to neuroinflammation in the hypothalamus. The hypothesis: blocking NLRP3 in the hypothalamus modulates dysfunctional neuronal circuitry controlling appetite, reducing food intake. Nick Brandon, Neumora's chief scientific officer, said the compound achieves sustained IC90 coverage in the brain.
In a diet-induced obesity mouse model, NMRA-215 produced what Brandon called class-leading weight loss as a monotherapy, including incretin-like induction. It also showed additive weight loss in combination with semaglutide and potential as a switch or maintenance treatment. Peripheral biomarkers tied to cardiometabolic risk improved as well. Brandon cited clinical data from other NLRP3 inhibitors showing decreases in CV risk factors, presenting that as supporting context for NMRA-215's expected profile.
The comparison carries a caveat the company's own forward-looking language includes: differences in compounds, study designs, and subject characteristics limit direct comparability between NMRA-215 and other NLRP3 programs.
What remains open before the IND lands
The toxicology package spans four completed studies: a 28-day rat study, a 28-day dog study, a 13-week dog study, and the now-cleared 13-week repeat rat study. One item flagged in the forward-looking risk disclosures: Neumora has not yet received or reviewed the histopathology report for the three-month toxicity study. The Q4 2026 IND filing and the Phase 1 start both remain projected, contingent on that report.